Skip to main content

Table 4 Adjusted Cox hazards regression models (including last CD4 and last viral load as independent variables) for patients who used antiretroviral therapy (N = 1878 individuals)

From: Predictors of opportunistic illnesses incidence in post combination antiretroviral therapy era in an urban cohort from Rio de Janeiro, Brazil

  Tuberculosis Esophageal candidiasis Cerebral Toxoplamosis PCP
  (N = 30) (N = 10) (N = 12) (N = 8)
  HR (CI) HR (CI) HR (CI) HR (CI)
Gender-Risk     
 Women Ref. Ref. Ref. Ref.
 Heterosexual men 0.82 (0.37–1.82) 0.16 (0.02–1.39) 1.10 (0.27–4.43) 0.90 (0.17–4.73)
 MSM 0.49 (0.16–1.48) 0.37 (0.06–2.24) 0.34 (0.04–2.71) 0.57 (0.08–4.09)
Age (per year) 1.02 (0.98–1.06) 0.94 (0.86–1.02) 0.90 (0.82–0.99) 1.07 (1.00–1.14)
Race/ethnicity     
 White Ref. Ref. Ref. Ref.
 Non-white 0.90 (0.41–2.00) 1.84 (0.35–9.51) 0.53 (0.14–1.92) 1.05 (0.21–5.19)
Educational level     
 0–8 years 1.89 (0.70–5.12) 1.05 (0.22–5.12) 1.46 (0.34–6.33) 0.44 (0.08–2.41)
 9+ years Ref. Ref. Ref. Ref.
Nadir CD4+ T lymphocyte (per 100 cells/mm3) 0.88 (0.62–1.24) 0.95 (0.50–1.79) 1.17 (0.85–1.61) 1.15 (0.73–1.83)
Last CD4+ Tlymphocyteª (per/100 cells/mm3) 0.95 (0.80–1.13) 0.87 (0.61–1.23) 0.70 (0.49–0.99) 1.09 (0.90–1.33)
Last HIV viral loadb     
 <400 copies/mm3 Ref. Ref. Ref. Ref.
 >400 copies/mm3 0.35 (0.08–1.56) 4.45 (0.98–20.19) 3.04 (0.73–12.58) 2.57 (0.42–15.88)
Opportunistic illness at enrollment 23.01 (9.44–56.09) 15.52 (3.38–71.30) 31.96 (8.31–123.88) 21.83 (2.85–167.29)
Time under cART (per year) 0.79 (0.63–0.99) 0.71 (0.40–1.28) 0.70 (0.44–1.12) 0.60 (0.33–1.08)
  1. cART combination antiretroviral therapy, PCP Pneumocystis jiroveci pneumonia, HR hazard ratio, CI 95 % confidence interval, MSM men who have sex with men
  2. ªData imputed for 333 individuals with missing last CD4
  3. bData imputed for 368 individuals with missing last HIV viral load
  4. Bold font implies statistically significant results assuming a 5 % significance threshold